CN107913281A - Isovitexin is preparing the application in treating laryngeal cancer medicine - Google Patents
Isovitexin is preparing the application in treating laryngeal cancer medicine Download PDFInfo
- Publication number
- CN107913281A CN107913281A CN201610878072.5A CN201610878072A CN107913281A CN 107913281 A CN107913281 A CN 107913281A CN 201610878072 A CN201610878072 A CN 201610878072A CN 107913281 A CN107913281 A CN 107913281A
- Authority
- CN
- China
- Prior art keywords
- isovitexin
- laryngeal cancer
- medicine
- cancer medicine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses Isovitexin to prepare the application in treating laryngeal cancer medicine, belongs to technical field of new application of medicine.The present invention is evaluated by external MTT antineoplastic activity and found, growths of the Isovitexin to human laryngeal cancer cell line HEP 2, TU 686, M2E and M4E also has significant inhibitory action.Therefore, Isovitexin can be used to prepare anti-laryngocarcinoma medicament, have good development prospect.Belong to first public for purposes of the Isovitexin of the present invention in treatment laryngeal cancer medicine is prepared, and it is unexpectedly strong for the inhibitory activity of laryngeal cancer cell.
Description
Technical field
The present invention relates to the new application of compound Isovitexin, more particularly to Isovitexin to prepare treatment laryngocarcinoma medicine
Application in thing.
Background technology
Cancer is one of disease maximum to human life and health harm, has substantial amounts of people to die of cancer every year.Anticancer
The research and development of medicine are always the hot spot of study of pharmacy.It is natural products or derivatives thereof to have 74% in antitumor drug, such as Japanese yew
Alcohol and its derivative are exactly the current clinically relatively good antitumor drug of application effect.Therefore, found from natural products anti-
Chemical compound for treating cancer or lead compound have great importance.
Compound Isovitexin of the present invention be one deliver within 2013 (Ebenezer de Mello Cruz,
et al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.) noval chemical compound, the compound possess brand-new framework types (Ebenezer de Mello Cruz, et al.,
Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.), belong to first public for purposes of the Isovitexin of the present invention in treatment laryngeal cancer medicine is prepared, due to
Belong to brand-new structure type, and it is unexpectedly strong for the inhibitory activity of laryngeal cancer cell, and there is no by other chemical combination
Thing provides the possibility of any enlightenment, possesses prominent substantive distinguishing features, at the same for laryngocarcinoma prevention obviously have significantly into
Step.
The content of the invention
It is an object of the invention to not find its report with anti-laryngeal cancer activity in being studied according to existing Isovitexin
Present situation, there is provided applications of the Isovitexin in anti-laryngocarcinoma medicament is prepared.
Shown in the compound Isovitexin structures such as formula (I)：
Applications of the Isovitexin in treatment laryngeal cancer medicine is prepared, laryngeal cancer cell behaviour laryngeal cancer cell strain HEP-2,
TU 686, M2E and M4E.
One kind treats laryngeal cancer medicine, and adding auxiliary material by Isovitexin for active ingredient is prepared, and preparation method is to take 5
G of compound Isovitexin, adds 195 grams of dextrin, mixes, and Conventional compression is made 1000.
One kind treats laryngeal cancer medicine, and adding auxiliary material by Isovitexin for active ingredient is prepared, and preparation method is to take 5
G of compound Isovitexin, adds 195 grams of starch, mixes, encapsulated to be made 1000.
The present invention is evaluated by external MTT antineoplastic activity and found, Isovitexin is to human laryngeal cancer cell line HEP-2, TU
686th, the growth of M2E and M4E also has significant inhibitory action, suppress this 4 plants of cell growths IC50 values be respectively 1.45 ±
0.53 μM, 1.44 ± 0.32 μM, 0.52 ± 0.63 μM and 0.42 ± 0.33 μM.Therefore, Isovitexin can be used to prepare anti-larynx
Cancer drug, has good development prospect.
Belong to first public for purposes of the Isovitexin of the present invention in treatment laryngeal cancer medicine is prepared, due to
Framework types belong to brand-new framework types, and it is unexpectedly strong for the inhibitory activity of laryngeal cancer cell, there is no by
Other compounds provide the possibility of any enlightenment, possess prominent substantive distinguishing features, while obviously have for the prevention of laryngocarcinoma
Significant progress.
The present invention is described in further detail by the following examples, but protection scope of the present invention is from specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment
The preparation method of compound Isovitexin involved in the present invention is referring to document (Ebenezer de Mello
Cruz, et al., Leishmanicidal activity of Cecropia pachystachya flavonoids:
Arginase inhibition and altered mitochondrial DNA arrangement.Phytochemistry,
89(2013)71–77.)
The present invention is described in further detail by the following examples, but protection scope of the present invention is from specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment 1：The preparation of compound Isovitexin tablets involved in the present invention：
5 g of compound Isovitexin are taken, add 195 grams of dextrin, are mixed, conventional tablet presses are made 1000.
Embodiment 2：The preparation of compound Isovitexin capsules involved in the present invention：
5 g of compound Isovitexin are taken, add 195 grams of starch, are mixed, it is encapsulated to be made 1000.
Its pharmaceutical activity is further illustrated below by pharmacodynamic experiment.
Experimental example：Growth inhibition effects of the compound Isovitexin to human laryngeal cancer cell line is evaluated using mtt assay
1. method：Cell in growth logarithmic phase：(purchase is certainly by human laryngeal cancer cell line HEP-2, TU 686, M2E and M4E
Chinese Academy of Sciences's cell bank) with 1.5 × 104Concentration kind is in 96 orifice plates.Original culture is sucked after cell culture 24h is adherent
Base.Experiment is divided into blank control group, drug-treated group.Blank group replaces 1640 culture mediums containing 10% hyclone；At medicine
Reason group replaces the culture containing the Isovitexin that concentration is 100 μM, 50 μM, 10 μM, 1 μM, 0.1 μM, 0.01 μM and 0.001 μM
Base.After cultivating 48h, the MTT of concentration 5mg/mL is added, continues to be put in CO2Incubator culture 4h, inhales then along nutrient solution top
100 μ L of supernatant are removed, add 100 μ L DMSO, 10min is placed in dark place, and extinction is measured using microplate reader (Sunrise Products)
It is worth (wavelength 570nm), and cell survival is calculated according to light absorption value, each processing sets 6 repeating holes.Cell survival rate (%)
=Δ OD drug-treateds/Δ OD blank control × 100.
2. result：Growths of the Isovitexin to human laryngeal cancer cell line HEP-2, TU 686, M2E and M4E has significant
Inhibitory action.It is respectively 1.45 that the compound, which suppresses human laryngeal cancer cell line HEP-2, TU 686, M2E and the IC50 values of M4E growths,
± 0.53 μM, 1.44 ± 0.32 μM, 0.52 ± 0.63 μM and 0.42 ± 0.33 μM.
Shown by above-described embodiment, Isovitexin of the invention to human laryngeal cancer cell line HEP-2, TU 686, M2E and
The growth of M4E has good inhibiting effect.Thus prove, Isovitexin of the invention has anti-laryngeal cancer activity, can be used for
Prepare anti-laryngocarcinoma medicament.
Claims (4)
- Applications of the 1.Isovitexin in laryngeal cancer medicine is treated, shown in the compound Isovitexin structures such as formula (I)：
- 2. applications of the Isovitexin as claimed in claim 1 in laryngeal cancer medicine is treated, it is characterised in that laryngeal cancer cell is behaved Laryngeal cancer cell strain HEP-2, TU 686, M2E and M4E.
- 3. one kind treats laryngeal cancer medicine, it is characterised in that Isovitexin adds auxiliary material for active ingredient as described in claim 1 It is prepared, preparation method adds 195 grams of dextrin, mix, Conventional compression is made 1000 to take 5 g of compound Isovitexin Piece.
- 4. one kind treats laryngeal cancer medicine, it is characterised in that Isovitexin adds auxiliary material for active ingredient as described in claim 1 It is prepared, preparation method adds 195 grams of starch, mixing is encapsulated to be made 1000 to take 5 g of compound Isovitexin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610878072.5A CN107913281A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating laryngeal cancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610878072.5A CN107913281A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating laryngeal cancer medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107913281A true CN107913281A (en) | 2018-04-17 |
Family
ID=61892133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610878072.5A Pending CN107913281A (en) | 2016-10-08 | 2016-10-08 | Isovitexin is preparing the application in treating laryngeal cancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107913281A (en) |
-
2016
- 2016-10-08 CN CN201610878072.5A patent/CN107913281A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107913281A (en) | Isovitexin is preparing the application in treating laryngeal cancer medicine | |
| CN107913269A (en) | Isovitexin is preparing the application in treating uterine neck cancer drug | |
| CN107913265A (en) | Isovitexin is preparing the application in treating medicine for nasopharyngeal | |
| CN107865860A (en) | Apigenin is preparing the application in treating uterine neck cancer drug | |
| CN107865838A (en) | Apigenin is preparing the application in treating laryngeal cancer medicine | |
| CN107865856A (en) | Apigenin is preparing the application in treating rectum cancer drug | |
| CN107913267A (en) | Isovitexin is preparing the application in treating blindgut cancer | |
| CN107837251A (en) | Apigenin is preparing the application in treating pancreatic cancer drug | |
| CN107865879A (en) | Orientin is preparing the application in treating skin cancer drug | |
| CN107837264A (en) | Apigenin is preparing the application in treating gastric cancer medicament | |
| CN107913280A (en) | Isovitexin is preparing the application in treating breast cancer medicines | |
| CN107837285A (en) | Isovitexin is preparing the application in treating tongue cancer drug | |
| CN107865835A (en) | Orientin is preparing the application in treating tongue cancer drug | |
| CN107913270A (en) | Isovitexin is preparing the application in treating bile duct cancer drug | |
| CN107865861A (en) | Apigenin is preparing the application in treating tongue cancer drug | |
| CN107865852A (en) | Apigenin is preparing the application in treating medicine for nasopharyngeal | |
| CN107865839A (en) | Apigenin is preparing the application in treating endometrial cancer drug | |
| CN107854459A (en) | Apigenin is preparing the application in treating bile duct cancer drug | |
| CN102885809B (en) | Application of Aphanamixoid A in preparing medicament for treating pancreatic cancer | |
| CN107865877A (en) | Orientin is preparing the application in treating prostate cancer medicine | |
| CN107865836A (en) | Orientin is preparing the application in treating ovarian cancer | |
| CN107837253A (en) | Isovitexin is preparing the application in treating rectum cancer drug | |
| CN107865855A (en) | Apigenin is preparing the application in treating breast cancer medicines | |
| CN107865863A (en) | Apigenin is preparing the application in treating blindgut cancer | |
| CN107854474A (en) | Orientin is preparing the application in treating kidney medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180417 |
|
| WD01 | Invention patent application deemed withdrawn after publication |